258 related articles for article (PubMed ID: 15449312)
1. Transcriptional activities of mutant p53: when mutations are more than a loss.
Kim E; Deppert W
J Cell Biochem; 2004 Nov; 93(5):878-86. PubMed ID: 15449312
[TBL] [Abstract][Full Text] [Related]
2. Transcription regulation by mutant p53.
Weisz L; Oren M; Rotter V
Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
[TBL] [Abstract][Full Text] [Related]
3. Interactions of mutant p53 with DNA: guilt by association.
Kim E; Deppert W
Oncogene; 2007 Apr; 26(15):2185-90. PubMed ID: 17401427
[TBL] [Abstract][Full Text] [Related]
4. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation.
Di Agostino S; Strano S; Emiliozzi V; Zerbini V; Mottolese M; Sacchi A; Blandino G; Piaggio G
Cancer Cell; 2006 Sep; 10(3):191-202. PubMed ID: 16959611
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53: an oncogenic transcription factor.
Strano S; Dell'Orso S; Di Agostino S; Fontemaggi G; Sacchi A; Blandino G
Oncogene; 2007 Apr; 26(15):2212-9. PubMed ID: 17401430
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
8. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
Thomas S; Reisman D
Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 proteins behave in a dominant, negative fashion in vivo.
Hachiya M; Chumakov A; Miller CW; Akashi M; Said J; Koeffler HP
Anticancer Res; 1994; 14(5A):1853-9. PubMed ID: 7847818
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants.
Zalcenstein A; Stambolsky P; Weisz L; Müller M; Wallach D; Goncharov TM; Krammer PH; Rotter V; Oren M
Oncogene; 2003 Aug; 22(36):5667-76. PubMed ID: 12944915
[TBL] [Abstract][Full Text] [Related]
11. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
12. Identification of ANKRD11 as a p53 coactivator.
Neilsen PM; Cheney KM; Li CW; Chen JD; Cawrse JE; Schulz RB; Powell JA; Kumar R; Callen DF
J Cell Sci; 2008 Nov; 121(Pt 21):3541-52. PubMed ID: 18840648
[TBL] [Abstract][Full Text] [Related]
13. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
Yeudall WA; Vaughan CA; Miyazaki H; Ramamoorthy M; Choi MY; Chapman CG; Wang H; Black E; Bulysheva AA; Deb SP; Windle B; Deb S
Carcinogenesis; 2012 Feb; 33(2):442-51. PubMed ID: 22114072
[TBL] [Abstract][Full Text] [Related]
14. Mutant p53 gain of function: the NF-Y connection.
Peart MJ; Prives C
Cancer Cell; 2006 Sep; 10(3):173-4. PubMed ID: 16959607
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic mutant p53 increases Bcl-2 expression in estrogen receptor-positive breast cancer cells.
Pratt MA; White D; Kushwaha N; Tibbo E; Niu MY
Apoptosis; 2007 Apr; 12(4):657-69. PubMed ID: 17252199
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences.
Chen JY; Funk WD; Wright WE; Shay JW; Minna JD
Oncogene; 1993 Aug; 8(8):2159-66. PubMed ID: 8336941
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction.
Buganim Y; Kalo E; Brosh R; Besserglick H; Nachmany I; Rais Y; Stambolsky P; Tang X; Milyavsky M; Shats I; Kalis M; Goldfinger N; Rotter V
Cancer Res; 2006 Nov; 66(22):10750-9. PubMed ID: 17108111
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effect of mutant and wild-type p53 on global gene expression.
O'Farrell TJ; Ghosh P; Dobashi N; Sasaki CY; Longo DL
Cancer Res; 2004 Nov; 64(22):8199-207. PubMed ID: 15548685
[TBL] [Abstract][Full Text] [Related]
19. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.
Kakudo Y; Shibata H; Otsuka K; Kato S; Ishioka C
Cancer Res; 2005 Mar; 65(6):2108-14. PubMed ID: 15781620
[TBL] [Abstract][Full Text] [Related]
20. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression.
Bon G; Di Carlo SE; Folgiero V; Avetrani P; Lazzari C; D'Orazi G; Brizzi MF; Sacchi A; Soddu S; Blandino G; Mottolese M; Falcioni R
Cancer Res; 2009 Jul; 69(14):5978-86. PubMed ID: 19567674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
